-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Receives Average Rating of "Moderate Buy" From Brokerages
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Receives Average Rating of "Moderate Buy" From Brokerages
Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) have been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.81.
A number of equities analysts recently issued reports on DNA shares. BTIG Research boosted their price objective on Ginkgo Bioworks from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday, August 16th. Jefferies Financial Group dropped their price objective on Ginkgo Bioworks from $11.50 to $4.35 in a report on Thursday, June 16th. Finally, Raymond James boosted their price objective on Ginkgo Bioworks from $11.50 to $14.50 and gave the company an "outperform" rating in a report on Tuesday, August 16th.
Get Ginkgo Bioworks alerts:Ginkgo Bioworks Trading Down 4.2 %
DNA opened at $2.94 on Wednesday. The business has a fifty day moving average of $2.97 and a 200 day moving average of $3.06. Ginkgo Bioworks has a 52-week low of $2.09 and a 52-week high of $15.86. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84.
Institutional Investors Weigh In On Ginkgo Bioworks
A number of institutional investors and hedge funds have recently bought and sold shares of the company. FDx Advisors Inc. bought a new position in shares of Ginkgo Bioworks in the 1st quarter worth $150,000. Exos Asset Management LLC raised its position in shares of Ginkgo Bioworks by 68.1% in the 1st quarter. Exos Asset Management LLC now owns 22,861 shares of the company's stock worth $92,000 after acquiring an additional 9,261 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Ginkgo Bioworks by 315.2% in the 4th quarter. Cubist Systematic Strategies LLC now owns 1,156,832 shares of the company's stock worth $9,613,000 after acquiring an additional 878,232 shares in the last quarter. FNY Investment Advisers LLC raised its position in shares of Ginkgo Bioworks by 17.6% in the 2nd quarter. FNY Investment Advisers LLC now owns 102,680 shares of the company's stock worth $244,000 after acquiring an additional 15,375 shares in the last quarter. Finally, Wealthstream Advisors Inc. bought a new position in shares of Ginkgo Bioworks in the 1st quarter worth $378,000. 53.37% of the stock is owned by institutional investors.About Ginkgo Bioworks
(Get Rating)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Further Reading
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) have been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.81.
据MarketBeat.com报道，Ginkgo Bioworks Holdings，Inc.(纽约证券交易所代码：DNA-GET Rating)的股票已被覆盖该股票的七家评级公司一致给予“适度买入”的建议。一位股票研究分析师对该股的评级为卖出，一位分析师给出了持有评级，四位分析师给出了该公司的买入评级。在过去一年发布该股报告的分析师中，1年目标价的平均水平为7.81美元。
A number of equities analysts recently issued reports on DNA shares. BTIG Research boosted their price objective on Ginkgo Bioworks from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday, August 16th. Jefferies Financial Group dropped their price objective on Ginkgo Bioworks from $11.50 to $4.35 in a report on Thursday, June 16th. Finally, Raymond James boosted their price objective on Ginkgo Bioworks from $11.50 to $14.50 and gave the company an "outperform" rating in a report on Tuesday, August 16th.
一些股票分析师最近发布了关于DNA股票的报告。BTIG Research在8月16日周二的一份报告中将他们对银杏生物工场的目标价从5.00美元上调至6.00美元，并给予该公司“买入”评级。在6月16日星期四的一份报告中，杰富瑞金融集团将银杏生物工程的目标价格从11.50美元下调至4.35美元。最后，雷蒙德·詹姆斯在8月16日星期二的一份报告中将银杏生物科技公司的目标价从11.50美元上调至14.50美元，并给予该公司“跑赢大盘”的评级。
Ginkgo Bioworks Trading Down 4.2 %
银杏生物工场股价下跌4.2%
DNA opened at $2.94 on Wednesday. The business has a fifty day moving average of $2.97 and a 200 day moving average of $3.06. Ginkgo Bioworks has a 52-week low of $2.09 and a 52-week high of $15.86. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84.
DNA周三开盘报2.94美元。该业务的50日移动均线切入位在2.97美元，200日移动均线切入位在3.06美元。银杏生物工场的52周低点为2.09美元，52周高位为15.86美元。该公司的负债权益比率为0.03，速动比率为11.78，流动比率为11.84。
Institutional Investors Weigh In On Ginkgo Bioworks
机构投资者参与银杏生物工程
About Ginkgo Bioworks
关于银杏生物工场
(Get Rating)
(获取评级)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
银杏生物工程控股公司及其子公司开发细胞编程平台。它的平台用于对细胞进行编程，以实现产品的生物生产，如新型疗法、食品配料和从石油中提取的化学品。该公司服务于各种终端市场，包括特种化学品、农业、食品、消费品和药品。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
- 免费获取StockNews.com关于银杏生物工程(DNA)的研究报告
- 3家航空公司股票陷入持有格局
- Roku股票下跌，但并未出局
- 如果你渴望价值，那就尝尝露丝的好客之道吧
- 福特在第三季度发出警告后是否正在反弹
- AMD股票是不是跌得太厉害了？
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
接受《银杏生物工场日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对银杏生物工程和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧